Oppenheimer & Co. Inc. lessened its stake in shares of Shire PLC (NASDAQ:SHPG) by 0.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,722 shares of the biopharmaceutical company’s stock after selling 9 shares during the period. Oppenheimer & Co. Inc.’s holdings in Shire PLC were worth $450,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Inspirion Wealth Advisors LLC increased its holdings in Shire PLC by 0.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 8 shares during the last quarter. Level Four Advisory Services LLC increased its holdings in Shire PLC by 0.5% during the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 13 shares during the last quarter. Thompson Davis & CO. Inc. increased its holdings in Shire PLC by 3.1% during the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the last quarter. Baldwin Investment Management LLC increased its holdings in Shire PLC by 1.4% during the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 23 shares during the last quarter. Finally, Hartford Financial Management Inc. increased its holdings in Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares during the last quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

Shares of Shire PLC (NASDAQ SHPG) opened at 158.46 on Friday. The stock has a market capitalization of $47.20 billion, a P/E ratio of 70.90 and a beta of 1.61. The company has a 50-day moving average of $153.42 and a 200-day moving average of $168.82. Shire PLC has a 52 week low of $139.36 and a 52 week high of $209.22.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, analysts anticipate that Shire PLC will post $14.93 EPS for the current year.

The business also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.

COPYRIGHT VIOLATION WARNING: “Shire PLC (SHPG) Shares Sold by Oppenheimer & Co. Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/16/shire-plc-shpg-shares-sold-by-oppenheimer-co-inc.html.

A number of analysts recently issued reports on SHPG shares. Stifel Nicolaus decreased their price objective on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a report on Friday, June 9th. Jefferies Group LLC reiterated a “buy” rating and set a $216.00 target price (down previously from $239.00) on shares of Shire PLC in a research report on Friday, June 9th. Royal Bank Of Canada set a $218.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a research report on Thursday, June 8th. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. Finally, ValuEngine upgraded shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $220.08.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.